Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies—the role of HAS2, SHB and HBEGF
Authors:
- Karolin EbertKEKarolin Ebert
- Ivonne HaffnerIHIvonne Haffner
- Gwen ZwingenbergerGZGwen Zwingenberger
- Simone KellerSKSimone Keller
- Elba RaimúndezERElba Raimúndez
- Robert GeffersRGRobert Geffers
- Ralph WirtzRWRalph Wirtz
- Elena BarbariaEBElena Barbaria
- Vanessa HolleriethVHVanessa Hollerieth
- Rouven ArnoldRARouven Arnold
- Axel WalchAWAxel Walch
- Jan HasenauerJHJan Hasenauer
Open Access
- 9 March 2022
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-17
Abstract
Background: The standard treatment for patients with advanced HER2-positive gastric cancer is a combination of the antibody trastuzumab and platin-fluoropyrimidine chemotherapy. As some patients do not respond to trastuzumab therapy or develop resistance during treatment, the search for alternative treatment options and biomarkers to predict therapy response is the focus of research. We compared the efficacy of trastuzumab and other HER-targeting drugs such as cetuximab and afatinib. We also hypothesized that treatment-dependent regulation of a gene indicates its importance in response and that it can therefore be used as a biomarker for patient stratification. Methods: A selection of gastric cancer cell lines (Hs746T, MKN1, MKN7 and NCI-N87) was treated with EGF, cetuximab, trastuzumab or afatinib for a period of 4 or 24 h. The effects of treatment on gene expression were measured by RNA sequencing and the resulting biomarker candidates were tested in an available cohort of gastric cancer patients from the VARIANZ trial or functionally analyzed in vitro. Results: After treatment of the cell lines with afatinib, the highest number of regulated genes was observed, followed by cetuximab and trastuzumab. Although trastuzumab showed only relatively small effects on gene expression, BMF, HAS2 and SHB could be identified as candidate biomarkers for response to trastuzumab. Subsequent studies confirmed HAS2 and SHB as potential predictive markers for response to trastuzumab therapy in clinical samples from the VARIANZ trial. AREG, EREG and HBEGF were identified as candidate biomarkers for treatment with afatinib and cetuximab. Functional analysis confirmed that HBEGF is a resistance factor for cetuximab. Conclusion: By confirming HAS2, SHB and HBEGF as biomarkers for anti-HER therapies, we provide evidence that the regulation of gene expression after treatment can be used for biomarker discovery. Trial registration. Clinical specimens of the VARIANZ study (NCT02305043) were used to test biomarker candidates.Keywords
Funding Information
- Technische Universität München
This publication has 28 references indexed in Scilit:
- Clinical impact of tumour biology in the management of gastroesophageal cancerNature Reviews Clinical Oncology, 2016
- The role of the Src Homology-2 domain containing protein B (SHB) in β cellsJournal of Molecular Endocrinology, 2015
- Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines: focus on the contribution of the AP-1 transcription factor.2015
- Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinomaJournal of Clinical Investigation, 2014
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trialThe Lancet Oncology, 2013
- Identification of the Cancer Cell Proliferation and Survival Functions of proHB-EGF by Using an Anti-HB-EGF AntibodyPLOS ONE, 2013
- Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell linesInternational Journal of Oncology, 2012
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell linesOncogene, 2003
- Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer.2002